Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Technology · ·
$77.84
▼ $2.52 (-3.1%)
Market data updated: 09/20 12:26 PM
Fundamentals updated: 09/19/2026
News analyzed: 09/20/2026
Market Cap
Not available
Day Range
$75.99 - $81.83
52-Week Range
$40.77 - $104.32
Beta
—
Next Earnings
29.10.2026
Support
$40.77
Resistance
$81.83
TEM is a stock from the Technology sector — Software, hardware, chip, and computing-services companies — revenue tied to the pace of innovation and upgrade cycles.
-10.6% (1Y)
Strengths: 17/29 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 83.4%
Growth
Biggest negative driver
Operating margin
Operating margin: -19.9% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
63
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
1d ago · $77.84
Evidence: Euphoria score crossed 55 (now 81)
What happened after
Still awaiting outcome
1d ago · $77.84
Evidence: FOMO score jumped from 40 to 70 day-over-day
What happened after
Still awaiting outcome
16d ago · $64.66
Evidence: Euphoria score crossed 55 (now 69)
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
68
Quality
58
Value
50
Momentum
92
Risk
48
Sentiment
92
Fundamental
25
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Tempus AI has centered on its growing prominence in the cancer diagnostics and AI-driven healthcare sectors. Analysts from Rothschild & Co and Roth Capital initiated neutral coverage with a $67 price target, highlighting its potential in personalized cancer vaccines and tumor sequencing as a key investment opportunity. The company’s CEO, Eric Lefkofsky, will speak at the Morgan Stanley Global Healthcare Conference, reinforcing its focus on next-gen cancer treatments amid broader industry trends like AI in drug discovery and the rising interest in cancer vaccine technologies.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Tempus AI, Inc.. News trend score: 92. Reason: 10 of the last 20 articles are positive, versus 3 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
72
🎯 Conviction (vs. Emotion)
46
Psychology
81
Fundamentals
25
Technical
92
Valuation
50
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
+53%
Market Narrative
84
Fundamental Reality
46
Narrative Gap
+38
🧠 StockIQ Psychologist
TEM’s psychology is dominated by a paradox: **euphoria (27)** persists despite weak momentum (-3.5% ROC) and a 200-day outperformance gap (+24.6%), while FOMO (13) and panic selling (9) remain muted. The narrative-reality gap (1) suggests traders may be overestimating resilience. Key tension: euphoria’s disconnect from recent price action could reflect overconfidence in fundamentals or anchoring to past highs. The open question is whether sentiment remains resilient or if volatility (1.18x ATR) will escalate as traders reassess the valuation premium.
Updated: 09/09/2026, 09:21 AM
What could change this?
👥 What the crowd believes
"Personalized cancer vaccines are creating a diagnostics investment opportunity beyond Moderna and Merck, with tumor sequencing at its center."
"Pharmaceutical research is being rebuilt around artificial intelligence faster than the industry can absorb it. Arizton values the global AI in drug discovery market at approximately $8.52 billion by 2030."
"analyst Jamie Clark initiates coverage on Tempus AI with a Neutral rating and announces Price Target of $67."
"The argument centers on a difficult-to-replicate combination: clinical data, diagnostics, software, and artificial intelligence operating inside."
🧠 Market Brain events driving this
📈 13D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock’s stark divide in methodology verdicts reveals a clash between value-driven conviction and cautionary skepticism. Benjamin Graham’s models—both defensive and enterprising—unanimously rate it as a standout opportunity, seeing deep undervaluation and statistical discounts, while Peter Lynch’s growth framework also leans bullish, suggesting the market hasn’t yet priced in its potential. In contrast, the more risk-averse and cyclical approaches—like those of Howard Marks (market cycle), Loeb, and Malkiel/Bogle—flag red flags, either warning of overvaluation, late-cycle risks, or the inefficiency of active selection over passive indexing. Meanwhile, methodologies like Veblen’s and Housel’s dismiss it outright, interpreting its volatility or speculative momentum as a sign of speculative excess rather than a sound investment. The middle ground, represented by Walter Bagehot’s liquidity focus and Smith’s neutral stance, offers a cautious nod to stability but stops short of full endorsement, highlighting how even liquidity can’t fully offset broader concerns about timing and risk.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 100
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 93
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 78
Positive trend — the price action Livermore looked for
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 73
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 48
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 47
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 43
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 26
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 25
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 23
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 9
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 4
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (11 bullish · 1 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-19.9%
Net Margin
-19.3%
EBITDA Margin
-19.9%
ROE
-49.9%
ROA
-10.8%
ROIC
—
EPS
-$1.41
Cash
$604.79M
Total Debt
—
Current Ratio
3.13
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$77.84
Estimated Fair Value (DCF)
-$35,015.09
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
⚠️ Extreme
Model output is extreme — likely a data/model limitation for this stock, not a reliable fair-value read.
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-298.92M | $-274.24M |
| 2 | 19.4% | $-356.84M | $-300.35M |
| 3 | 13.8% | $-405.91M | $-313.43M |
| 4 | 8.1% | $-438.89M | $-310.92M |
| 5 | 2.5% | $-449.86M | $-292.38M |
Base FCF (last actual year)
$-239.14M
Terminal Value
$-7.09B
Present Value of Terminal Value
$-4.61B
Enterprise Value
$-6.10B
Net Debt
$0
Equity Value
$-6.10B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$2,819.43
Tangible Book Value per Share (Tangible NAV)
-$1,917.42
Sentiment based on basic keywords (not AI) — 10 positive, 7 neutral, 3 negative out of the last 20 articles.
Yahoo · 18.9.2026
Benzinga · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Benzinga · 17.9.2026
Benzinga · 17.9.2026
Benzinga · 16.9.2026
Benzinga · 16.9.2026
Yahoo · 15.9.2026
Benzinga · 15.9.2026
SeekingAlpha · 15.9.2026
Benzinga · 14.9.2026
MT Newswires · 11.9.2026
Yahoo · 11.9.2026
Business Wire · 11.9.2026
Benzinga · 11.9.2026
Benzinga · 11.9.2026
Tempus AI, Inc. (TEM) currently has a StockIQ AI score of 63/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
TEM currently scores 63/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
TEM's technical score is 92/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 83.4%; Earnings per share (EPS) growth: 77.4%; Net income growth: 65.3%.
Based on the real signals StockIQ computed: Operating margin: -19.9% (negative); Net margin: -19.3% (negative); ATR: 6.3% of price.
StockIQ has no recorded dividend payment history for TEM.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 25 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Fukushima Ryan | Open Market Sale | 1.9.2026 | 1,000 | -1,000 | $64.63 |
| Fukushima Ryan | Open Market Sale | 1.9.2026 | 10,900 | -10,900 | $62.64 |
| Epstein David R | Open Market Sale | 1.9.2026 | 250 | -250 | $65.55 |
| Fukushima Ryan | Open Market Sale | 1.9.2026 | 5,900 | -5,900 | $63.80 |
| Doudna Jennifer A | Open Market Sale | 1.9.2026 | 676 | -676 | $65.55 |
| Fukushima Ryan | Open Market Sale | 1.9.2026 | 13,046 | -13,046 | $62.12 |
| West Nadja | Open Market Sale | 28.8.2026 | 3,000 | -3,000 | $69.00 |
| LEFKOFSKY ERIC P | Open Market Sale | 25.8.2026 | 8,717,023 | -760 | $64.03 |
| LEFKOFSKY ERIC P | Open Market Sale | 25.8.2026 | 8,714,855 | -2,168 | $64.70 |
| LEFKOFSKY ERIC P | Open Market Sale | 25.8.2026 | 8,710,911 | -3,944 | $65.98 |
| LEFKOFSKY ERIC P | Open Market Sale | 25.8.2026 | 15,205,229 | -24,161 | $68.13 |
| LEFKOFSKY ERIC P | Open Market Sale | 25.8.2026 | 8,661,065 | -12,851 | $69.83 |
| LEFKOFSKY ERIC P | Open Market Sale | 25.8.2026 | 15,120,469 | -1,837 | $70.58 |
| LEFKOFSKY ERIC P | Open Market Sale | 25.8.2026 | 8,696,411 | -10,282 | $68.13 |
| LEFKOFSKY ERIC P | Open Market Sale | 25.8.2026 | 824,530 | -101 | $64.03 |
| LEFKOFSKY ERIC P | Open Market Sale | 25.8.2026 | 15,122,306 | -30,139 | $69.83 |
| LEFKOFSKY ERIC P | Open Market Sale | 25.8.2026 | 15,253,680 | -1,789 | $64.03 |
| LEFKOFSKY ERIC P | Open Market Sale | 25.8.2026 | 15,248,587 | -5,093 | $64.70 |
| LEFKOFSKY ERIC P | Open Market Sale | 25.8.2026 | 8,660,283 | -782 | $70.58 |
| LEFKOFSKY ERIC P | Open Market Sale | 25.8.2026 | 15,239,325 | -9,262 | $65.98 |
| LEFKOFSKY ERIC P | Open Market Sale | 25.8.2026 | 15,152,445 | -52,784 | $68.97 |
| LEFKOFSKY ERIC P | Open Market Sale | 25.8.2026 | 15,229,390 | -9,935 | $67.01 |
| LEFKOFSKY ERIC P | Open Market Sale | 25.8.2026 | 8,673,916 | -22,495 | $68.97 |
| LEFKOFSKY ERIC P | Open Market Sale | 25.8.2026 | 8,706,693 | -4,218 | $67.01 |
| LEFKOFSKY ERIC P | Open Market Sale | 25.8.2026 | 194,028 | -3,429 | $65.98 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
29,464,296 shares short as of 2026-08-31 · vs. 33,229,165 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
44.4% of trading volume this week was short selling, vs. 41.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology